Xiao Bao

机构：Shanghai Pulmonary Hospital · ORCID：0000-0002-4196-6691

发表论文 36 篇 · 总被引 382 次 · h-index 12

代表论文

• 99m Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen (2017 · Nuclear Medicine and Biology · 被引 57)
• Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study (2023 · Nature Communications · 被引 46)
• Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters (2016 · Theranostics · 被引 33)
• 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer (2015 · Oncotarget · 被引 29)
• Multi-functional self-assembled nanoparticles for pVEGF-shRNA loading and anti-tumor targeted therapy (2019 · International Journal of Pharmaceutics · 被引 27)
• MicroRNA‑23a‑5p regulates cell proliferation, migration and inflammation of TNF‑α‑stimulated human fibroblast‑like MH7A synoviocytes by targeting TLR4 in rheumatoid arthritis (2021 · Experimental and Therapeutic Medicine · 被引 22)